ADAG

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Adagene Inc

NASDAQ | ADAG

2.01

USD

+$0.00

(

+0.00%

)

At Close (As of Dec 3, 2025)

$84.84M

Market Cap

-

P/E Ratio

-0.64

EPS

$3.16

52 Week High

$1.30

52 Week Low

HEALTHCARE

Sector

ADAG Chart

Recent Chart
Price Action

ADAG Technicals

Tags:

ADAG Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$823K
Total Revenue $103K
Cost Of Revenue $926K
Costof Goods And Services Sold $926K
Operating Income -$36M
Selling General And Administrative $7.3M
Research And Development $29M
Operating Expenses $36M
Investment Income Net -
Net Interest Income $2.9M
Interest Income $3.8M
Interest Expense $852K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $926K
Income Before Tax -$33M
Income Tax Expense -$18K
Interest And Debt Expense -
Net Income From Continuing Operations -$33M
Comprehensive Income Net Of Tax -
Ebit -$33M
Ebitda -$32M
Net Income -$33M

Revenue & Profitability

Earnings Performance

ADAG Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $89M
Total Current Assets $88M
Cash And Cash Equivalents At Carrying Value $85M
Cash And Short Term Investments $85M
Inventory -
Current Net Receivables $8.3K
Total Non Current Assets $1.5M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $2.6M
Other Non Current Assets -
Total Liabilities $39M
Total Current Liabilities $38M
Current Accounts Payable $4.2M
Deferred Revenue -
Current Debt -
Short Term Debt $18M
Total Non Current Liabilities $560K
Capital Lease Obligations $284K
Long Term Debt $417K
Current Long Term Debt $18M
Long Term Debt Noncurrent -
Short Long Term Debt Total $18M
Other Current Liabilities $16M
Other Non Current Liabilities -
Total Shareholder Equity $51M
Treasury Stock -
Retained Earnings -$311M
Common Stock $5.9K
Common Stock Shares Outstanding $36M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$30M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $926K
Capital Expenditures $34K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $1.1M
Cashflow From Financing $3.8M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $0
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$33M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$823K
Total Revenue $103K
Cost Of Revenue $926K
Costof Goods And Services Sold $926K
Operating Income -$36M
Selling General And Administrative $7.3M
Research And Development $29M
Operating Expenses $36M
Investment Income Net -
Net Interest Income $2.9M
Interest Income $3.8M
Interest Expense $852K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $926K
Income Before Tax -$33M
Income Tax Expense -$18K
Interest And Debt Expense -
Net Income From Continuing Operations -$33M
Comprehensive Income Net Of Tax -
Ebit -$33M
Ebitda -$32M
Net Income -$33M

ADAG News

ADAG Profile

Adagene Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Adagene Inc. is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focusing on the innovative development of monoclonal antibody therapies for oncology. Leveraging its proprietary technologies, Adagene is pioneering next-generation antibody drug candidates aimed at improving efficacy and reducing side effects in cancer treatment. With a robust pipeline of drug candidates, the company is well-positioned to make significant advancements in the biopharmaceutical landscape, targeting unmet medical needs in cancer care.

LPTX
+368.57%
$2.05
VRAX
+69.66%
$0.66
VHAI
0.00%
$0.00
IXHL
+6.40%
$0.42
TWOH
0.00%
$0.00
PAVS
-23.95%
$0.04
IPG
-1.95%
$24.57
AXDX
-61.36%
$0.03
IRBT
+46.15%
$2.85
BBD
+1.38%
$3.67
NVDA
-0.27%
$180.95
ONDS
-3.71%
$7.77
ADAP
-15.14%
$0.05
MARA
+3.38%
$11.91
DNN
+2.77%
$2.59
PFE
-0.47%
$25.15
SOND
-23.45%
$0.12
NIO
-4.61%
$4.79
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
QCLS
+21.30%
$4.10
ITUB
+2.64%
$7.89
SRM
+53.27%
$10.30
BYND
-5.03%
$1.22
INTC
+0.01%
$43.47
PLTD
-1.83%
$6.96
VALE
+1.57%
$12.89
TSLA
+3.31%
$443.46
BURU
-0.76%
$0.21
WLGS
-5.57%
$0.04
ASST
-0.96%
$1.02
MTSR
-0.35%
$70.50
RR
+6.74%
$3.80
NFLX
+0.20%
$109.35
CAPR
+314.93%
$26.39
INHD
-8.22%
$0.13
BITF
-2.05%
$3.03
AFMD
-34.94%
$0.18
IREN
+2.42%
$42.11
IMRN
-2.29%
$1.70
LUMN
+10.25%
$9.14
AMCR
-1.63%
$8.40
PMAX
+25.99%
$2.86
MRVL
+6.12%
$98.58
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
HTOO
+15.80%
$4.05
BMNU
+13.35%
$8.32
PLTZ
-3.85%
$6.99
SOFI
+0.86%
$29.76
BMNR
+7.01%
$34.15
CMND
-20.37%
$0.10
PLUG
+1.42%
$2.14
KDLY
-2.95%
$0.48
CHR
-7.42%
$0.03
AAL
+0.87%
$14.36
SAND
-6.04%
$12.12
BMY
-1.89%
$48.25
CDE
-2.41%
$16.55
AUR
0.00%
$3.99
SHOT
-74.37%
$0.39
VIVK
-6.01%
$0.10
ZAPP
-46.30%
$0.15
NCLH
-0.75%
$18.43
ASBP
-9.00%
$0.09
ARTL
-2.77%
$1.75
KXIN
+30.48%
$4.04
AAPL
+0.03%
$286.29
CIFR
+0.73%
$17.77
AMD
+1.25%
$217.95
ALIT
-5.50%
$2.23
WULF
-2.26%
$13.89
CPNG
+0.22%
$26.71
AEO
+15.38%
$24.03
GTLB
-14.28%
$37.17
PLTR
+1.44%
$173.15
AMZN
-0.75%
$232.65
PSTG
+6.96%
$94.72
SONN
-59.35%
$1.26
F
+0.73%
$13.05
PFSA
+9.92%
$0.17
YGMZ
-12.76%
$0.07
FTRK
+14.28%
$0.44
ASAN
+4.85%
$13.39
PRMB
-0.48%
$16.33
GOOGL
+0.47%
$317.30
HOOD
+3.51%
$130.38
GM
+0.97%
$73.66
TLRY
-1.45%
$7.71
TEVA
+0.59%
$26.88
APH
+1.63%
$141.49
ACHR
+3.00%
$7.88
M
-1.21%
$22.43
CLSK
+1.09%
$13.86
CMCT
+9.45%
$3.82
IVP
-14.60%
$0.10
QBTS
+1.77%
$22.90
NWL
-3.67%
$3.67
VGFC
-1.90%
$0.05
LPTX
+368.57%
$2.05
VRAX
+69.66%
$0.66
VHAI
0.00%
$0.00
IXHL
+6.40%
$0.42
TWOH
0.00%
$0.00
PAVS
-23.95%
$0.04
IPG
-1.95%
$24.57
AXDX
-61.36%
$0.03
IRBT
+46.15%
$2.85
BBD
+1.38%
$3.67
NVDA
-0.27%
$180.95
ONDS
-3.71%
$7.77
ADAP
-15.14%
$0.05
MARA
+3.38%
$11.91
DNN
+2.77%
$2.59
PFE
-0.47%
$25.15
SOND
-23.45%
$0.12
NIO
-4.61%
$4.79
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
QCLS
+21.30%
$4.10
ITUB
+2.64%
$7.89
SRM
+53.27%
$10.30
BYND
-5.03%
$1.22
INTC
+0.01%
$43.47
PLTD
-1.83%
$6.96
VALE
+1.57%
$12.89
TSLA
+3.31%
$443.46
BURU
-0.76%
$0.21
WLGS
-5.57%
$0.04
ASST
-0.96%
$1.02
MTSR
-0.35%
$70.50
RR
+6.74%
$3.80
NFLX
+0.20%
$109.35
CAPR
+314.93%
$26.39
INHD
-8.22%
$0.13
BITF
-2.05%
$3.03
AFMD
-34.94%
$0.18
IREN
+2.42%
$42.11
IMRN
-2.29%
$1.70
LUMN
+10.25%
$9.14
AMCR
-1.63%
$8.40
PMAX
+25.99%
$2.86
MRVL
+6.12%
$98.58
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
HTOO
+15.80%
$4.05
BMNU
+13.35%
$8.32
PLTZ
-3.85%
$6.99
SOFI
+0.86%
$29.76
BMNR
+7.01%
$34.15
CMND
-20.37%
$0.10
PLUG
+1.42%
$2.14
KDLY
-2.95%
$0.48
CHR
-7.42%
$0.03
AAL
+0.87%
$14.36
SAND
-6.04%
$12.12
BMY
-1.89%
$48.25
CDE
-2.41%
$16.55
AUR
0.00%
$3.99
SHOT
-74.37%
$0.39
VIVK
-6.01%
$0.10
ZAPP
-46.30%
$0.15
NCLH
-0.75%
$18.43
ASBP
-9.00%
$0.09
ARTL
-2.77%
$1.75
KXIN
+30.48%
$4.04
AAPL
+0.03%
$286.29
CIFR
+0.73%
$17.77
AMD
+1.25%
$217.95
ALIT
-5.50%
$2.23
WULF
-2.26%
$13.89
CPNG
+0.22%
$26.71
AEO
+15.38%
$24.03
GTLB
-14.28%
$37.17
PLTR
+1.44%
$173.15
AMZN
-0.75%
$232.65
PSTG
+6.96%
$94.72
SONN
-59.35%
$1.26
F
+0.73%
$13.05
PFSA
+9.92%
$0.17
YGMZ
-12.76%
$0.07
FTRK
+14.28%
$0.44
ASAN
+4.85%
$13.39
PRMB
-0.48%
$16.33
GOOGL
+0.47%
$317.30
HOOD
+3.51%
$130.38
GM
+0.97%
$73.66
TLRY
-1.45%
$7.71
TEVA
+0.59%
$26.88
APH
+1.63%
$141.49
ACHR
+3.00%
$7.88
M
-1.21%
$22.43
CLSK
+1.09%
$13.86
CMCT
+9.45%
$3.82
IVP
-14.60%
$0.10
QBTS
+1.77%
$22.90
NWL
-3.67%
$3.67
VGFC
-1.90%
$0.05
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.